Tumour microenvironment and heterotypic interactions in pancreatic cancer
J. physiol. biochem
; 79(1): 179-192, feb. 2023.
Artigo
em Inglês
| IBECS
| ID: ibc-215723
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Pancreatic ductal adenocarcinoma (PDA) is a disease with a survival rate of 9%; this is due to its chemoresistance and the large tumour stroma that occupies most of the tumour mass. It is composed of a large number of cells of the immune system, such as Treg cells, tumour-associated macrophages (TAMs), myeloid suppressor cells (MDCs) and tumour-associated neutrophiles (TANs) that generate an immunosuppressive environment by the release of inflammatory cytokines. Moreover, cancer-associated fibroblast (CAFs) provide a protective coverage that would difficult the access of chemotherapy to the tumour. According to this, new therapies that could remodel this heterogeneous tumour microenvironment, such as adoptive T cell therapies (ACT), immune checkpoint inhibitors (ICI), and CD40 agonists, should be developed for targeting PDA. This review organizes the different cell populations found in the tumour stroma involved in tumour progression in addition to the different therapies that are being studied to counteract the tumour. (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Pancreáticas
/
Carcinoma Ductal Pancreático
Limite:
Humanos
Idioma:
Inglês
Revista:
J. physiol. biochem
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
Francisco de Vitoria University/Spain